Management of limited small-cell lung cancer

International Journal of Clinical Oncology

Volumn 5, Issue 4, 2000, Pages 205-216

  Komaki, R ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Lung; Prognostic factors; Small cell lung cancer; Treatment

Indexed keywords

ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; LACTATE DEHYDROGENASE; MITOMYCIN; PACLITAXEL; PREDNISONE; SODIUM; VINCRISTINE; VINCRISTINE SULFATE;

CANCER INCIDENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG SENSITIVITY; HUMAN; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; REVIEW; SKULL IRRADIATION;

EID: 0033831669     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00012040     Document Type: Review

References (43)

1. Cancer statistics
2. Influence of age on the treatment of limited stage small-cell lung cancer
3. Lung cancer biology
4. Small-cell lung cancer: The new biology
5. The clinical significance of variant-morphology small-cell carcinoma of the lung
6. Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation
7. Oncology practice guidelines. Small-cell lung cancer
8. Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D-glucose
9. Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. Ten-year follow-up
10. Small-cell bronchogenic carcinoma: A review of therapeutic results
11. Treatment of small-cell lung cancer
12. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis
13. A meta-analysis of thoracic radiotherapy for small-cell lung cancer
14. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer
15. Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: Comparison of sequential phase II trials using different dose-intensities
16. Small-cell carcinoma of the lung: Attempt to remedy causes of past therapeutic failure
17. Concurrent chemotherapy/radiotherapy for limited small-cell lung carcinoma: A Southwest Oncology Group study
18. Patterns of failure and second malignancies from SWOG-8629: Concurrent cisplatin, etoposide, vincristine, and once daily radiotherapy for the treatment of limited small-cell lung cancer
19. Limited stage small-cell lung cancer treated with concurrent hyperfractionated chest radiotherapy and etoposide/cisplatin
20. Long-term results of platinum, etoposide and twice daily thoracic radiotherapy for limited small-cell lung cancer: Results of 32 patients with 48 month minimum follow-up
21. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide
22. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer
23. The experimental basis of new strategies in combining chemotherapy and radiotherapy
24. Alternating radiotherapy and chemotherapy schedules in limited small-cell lung cancer: Analysis of local chest recurrences
25. Interdigitating versus concurrent chemotherapy and radiotherapy for limited small-cell lung cancer
26. Daily vs twice-daily thoracic irradiation with concurrent cisplatin/etoposide chemotherapy as initial therapy for patients with limited small-cell lung cancer: Preliminary results of a phase III prospective intergroup trial
27. Concurrent cisplatin-etoposide chemotherapy plus thoracic radiotherapy for limited stage small-cell lung cancer
28. Final results of a phase III study of concurrent versus sequential thoracic radiotherapy (TRT) in combination with cisplatin (P) and etoposisude (E) for limited-stage small-cell lung cancer (LD-SCLC): The Japan Clinical Oncology Group (JCOG) study
29. Dose response in small cell carcinoma
30. The effect of dose of thoracic irradiation on recurrence in patients with limited stage small-cell lung cancer. Initial results of a Canadian Multicenter randomized trial
31. Alternating radiotherapy and chemotherapy in 173 consecutive patients with limited small-cell lung carcinoma. GROP and the French Cancer Center's Lung Group
32. Phase I study to determine the maximum tolerated dose of radiation in standard daily and hyperfractionated accelerated twice daily radiation schedules with concurrent chemotherapy for limited stage small-cell lung cancer
33. Multimodal therapy for limited small-cell lung cancer: A randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: A Southwest Oncology Group study
34. Limited-stage small-cell lung cancer: Patterns of intrathoracic recurrence and the implications for thoracic radiotherapy
35. Risk of brain metastasis from small-cell carcinoma of the lung related to length of survival and prophylactic irradiation
36. CNS metastases in small-cell bronchogenic carcinoma: Increasing frequency and changing pattern with lengthening survival
37. Results of whole brain irradiation for metastases from small-cell carcinoma of the lung
38. What is the lowest effective biologic dose for prophylactic cranial irradiation?
39. Evaluation of cognitive function in patients with limited small-cell lung cancer prior to and shortly following prophylactic cranial irradiation
40. Analysis of long-term survival and impact of prophylactic cranial irradiation in complete responders with small-cell lung cancer: Analysis of the Mayo Clinic and North Central Cancer Treatment Group data bases
41. Neurological and cognitive impairment in long-term survivors of small-cell lung cancer
42. Patients with limited stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine
43. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission